… drug development. Compared to developing a drug de novo, drug repositioning may
reduce the drug development period to 6.5 years and the cost for repositioning a drug is $300 …

… (Graph-based Prior Knowledge) for improving in silico drug repositioning via using the prior
… (2) We propose a multimodal framework that combines the prior knowledge with two types …

… not need prior knowledge, and the repositioned drugs are just … knowledge about the targets,
such as 3D protein structures, whereas knowledge-based methods require the knowledge …

… The authors used a Bayesian statistics approach to rank drug-disease relationships according
to prior knowledge. Then, they integrated ranked relationships with other biological entity …

… The safety information in the drug labels is usually obtained in the clinical trial and augmented
with the observations in the post-market use of the drug. Therefore, our drug repositioning …

… prior knowledge that enable repositioning of drugs through clinical trials, these occurrences
are often serendipitous and rare. One challenge in drug repositioning, … for a drug of interest. …

… Under this new light, I believe that the interest on drug repositioning will continue to grow
vigorously in the short- and mid-term, as known drugs are repurposed for particular subtypes of …

… In summary, the geometric prior knowledge of HIN is of benefit for DDAGDL to correctly
capture its full complexity and structural richness in a non-Euclidean domain, and the proposed …

… cell lines after treatment, or on drug-to-disease relationships, … Here we focused on a
drug-centered approach by predicting … approach to predict drug repositioning based on …

… drugs. One significant advantage of drug repositioning over traditional drug development
is that … First, our approach requires some prior knowledge about the drugs, eg, its chemical …